Abstract
Background The novel chimeric natriuretic peptide, CD-NP, is a Mayodesigned cGMP-activating synthetic peptide that consists of the 22-amino-acid (AA) residues of C-type natriuretic peptide (CNP) and the 15-AA C-terminal extension of Dendroaspis natriuretic peptide (DNP) [1]. The rationale for the design of CD-NP was to transform CNP, which activates natriuretic peptide receptor-B (NPR-B) and is natriuretic, diuretic and less hypotensive than ANP and BNP which activate NPR-A into a CNP-like peptide with added renal actions. The goal of this investigation was to directly compare the cardiorenal profile of CD-NP to that of CNP.
Highlights
The novel chimeric natriuretic peptide, CD-NP, is a Mayodesigned cGMP-activating synthetic peptide that consists of the 22-amino-acid (AA) residues of C-type natriuretic peptide (CNP) and the 15-AA C-terminal extension of Dendroaspis natriuretic peptide (DNP) [1]
Glomerular filtration rate was enhanced by CD-NP (37 ± 2*‡ to 48 ± 3† to 51 ± 3† to 53 ± 4† ml/min) and was preserved by CNP (55 ± 5 to 57 ± 6 to 52 ± 4 to 50 ± 6 ml/min)
Pulmonary capillary wedge pressure was significantly reduced by CDNP (5.7 ± .7 to 4.1 ± 1* to 3.2 ± .7†‡ to 4.3 ± .8 mmHg), but not by CNP (5.8 ± .7 to 5.7 ± .8 to 6.7 ± .7 to 7.4 ± .9† mmHg)
Summary
The novel chimeric natriuretic peptide, CD-NP, is a Mayodesigned cGMP-activating synthetic peptide that consists of the 22-amino-acid (AA) residues of C-type natriuretic peptide (CNP) and the 15-AA C-terminal extension of Dendroaspis natriuretic peptide (DNP) [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
